JP Morgan Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) but lowers the price target from $46 to $43.
August 07, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on BridgeBio Pharma but lowers the price target from $46 to $43.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100